Colitis with Hypereosinophilia Following the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine: A Case Report with a Literature Review

Tsuyoshi Doman; Hiroaki Saito; Yukari Tanaka; Dai Hirasawa; Mareyuki Endo; Daichi Togo; Tomoki Matsuda

doi:10.2169/internalmedicine.0518-22

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Colitis with Hypereosinophilia Following the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine: A Case Report with a Literature Review

Tsuyoshi Doman, Hiroaki Saito, Yukari Tanaka, Dai Hirasawa, Mareyuki Endo, Daichi Togo, Tomoki Matsuda

著者情報

キーワード: COVID-19, mRNA, vaccine, diarrhea, hypereosinophilia

ジャーナルオープンアクセス早期公開

論文ID: 0518-22

DOI https://doi.org/10.2169/internalmedicine.0518-22

この記事には本公開記事があります。

The final version of this article is now available: Vol. 62 (2023), No. 6 pp. 865-869

詳細

抄録

A 61-year-old man presented with a 7-day history of watery diarrhea and loss of appetite after receiving the second dose of the Pfizer-BioNTech Covid-19 vaccine. Laboratory studies showed significant eosinophilia and an elevated IgE level (white cell count, 18.4×10⁹/L; eosinophil count, 9.5×10⁹/L; and IgE level, 540 IU/L). Symptoms resolved 10 days after vaccination without any steroids or antiallergic medications, and the eosinophil count had also returned to within normal limits 2 months later. Several cases of eosinophilic disorders following receipt of any type of injectable COVID-19 vaccine have been reported, so the etiology should be examined.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）